11β-Hydroxysteroid dehydrogenase (11β-HSD1) is an enzyme that catalyses the transformation of the inactive glucocorticoid cortisone into active cortisol. A chronically elevated level of cortisol as a result of 11β-HSD1 hyperexpression in the liver and fatty tissue leads to the development of metabolic syndrome, obesity, insulin-resistance, type 2 diabetes mellitus (DM2), and cardiovascular complications. Inhibition of 11β-HSD1 is recognized as a promising strategy for reducing the activity of glucocorticoids on a tissue-specific level. Herein inhibitors of 11β-HSD1, representatives of several types of N-containing heterocycles at various research stages, are reviewed as potential drugs influencing metabolic syndrome, DM2, and obesity.
Similar content being viewed by others
References
W. Artl, P. M. Stewart, Endocrinol. Metab. Clin. North Am., 34, 293–313 (2005).
L. Jacobson, Endocrinol. Metab. Clin. North Am., 34, 271–292 (2005).
T. P. Bezverkhaya, N. D. Tron’ko, Endokrinologiya, 13(1), 117–135 (2008).
A. G. Atanasov, A. Odermatt, Endocrine, Metabolic & Immune Disorders - Drug Targets, 7, 125–140 (2007).
P. M. Stewart, Clin. Med., 5, 142–146 (2005).
J. Newell-Price, X. Bertagna, A. B. Grossman, Lancet, 367, 1605–1617 (2006).
J. W. Tomlinson, P. M. Stewart, J. Endocrinol. Invest., 27, 171–174 (2004).
D. Amelung, H. J. Huebner, L. Roka, J. Clin. Endocrinol. Metab., 13, 1125 (1953).
J. R. Seckl, B. R. Walker, Endocrinology, 142(4), 1371–1376 (2001).
P. M. Stewart, Z. S. Krozowski, Vitam. Horm., 57, 249–324 (1999).
P. Arnold, S. Tam, L. Yan, et al., Mol. Cell. Endocrinol., 201, 177–187 (2003).
P. M. Jamieson, B. R. Walker, K. E. Chapman, et al., J. Endocrinol., 165, 685–692 (2000).
I. J. Bujalska, E. A. Walker, M. Hewison, et al., J. Clin. Endocrinol. Metab., 87, 1205–1210 (2002).
A. G. Atanasov, L. G. Nashev, R. A. Scheweizer, et al., FEBS Lett., 571, 129–133 (2004).
P. M. Stewart, Z. S. Krozowski, A. Gupta, et al., Lancet, 347, 88–91 (1996).
M. Wamil, J. R. Seckl, Drug Discovery Today, 12(13/14), 504–520 (2007).
K. Kannisto, K. H. Pietilainen, E. Ehrenborg, et al., J. Clin. Endocrinol. Metab., 89, 4414–4421 (2004).
P. M. Stewart, A. Boulton, S. Kumar, et al., J. Clin. Endocrinol. Metab., 84, 1022–1027 (1999).
S. K. Paulsen, S. B. Pedersen, S. Fisker, et al., Obesity, 15(8), 1954–1960 (2007).
J. Berger, M. Tanen, A. Elbrecht, et al., J. Biol. Chem., 276, 12629–12636 (2001).
M. Laplante, H. Sell, K. L. MacNaul, et al., Diabetes, 52, 291–299 (2003).
L. Duplomb, Y. Lee, M. Y. Wang, et al., Biochem. Biophys. Res. Commun., 313, 594–599 (2004).
G. G. Lavery, E. A. Walker, A. Tiganescu, et al., J. Clin. Endocrinol. Metab., 93, 3827–3832 (2008).
M. S. Cooper, P. M. Stewart, J. Clin. Endocrinol. Metab., 94, 4645–4654 (2009).
J. W. Chu, D. F. Matthias, J. Belanoff, et al., J. Clin. Endocrinol. Metab., 86, 3568–3573 (2001).
C. Fotsch, M. Wang, J. Med. Chem., 51, 4851–4857 (2008).
H. Masuzaki, J. Paterson, H. Shinyama, et al., Science, 294, 2166–2170 (2001).
N. M. Morton, J. Paterson, H. Masuzaki, et al., Diabetes, 53, 913–938 (2004).
J. Xiang, Z.-K. Wan, H.-Q. Li, et al., J. Med. Chem., 51, 4068–4071 (2008).
H. Masuzaki, H. Yamamoto, C. J. Kenyon, et al., J. Clin. Invest., 112, 83–90 (2003).
S. A. Latif, M. F. Sheff, C. E. Ribeiro, et al., Steroids, 62, 230–237 (1997).
S. Arampatzis, B. Kadereit, D. Schuster, et al., J. Mol. Endocrinol., 35, 89–101 (2005).
G. A. Tolstikov, L. A. Baltina, N. G. Serdyuk, Khim-farm. Zh., 32(8), 5–14 (1998).
A. M. Nuotio-Antar, D. L. Hachey, A. H. Hasty, Am. J. Physiol.: Endocrinol. Metab., 293, E1517–E1528 (2007).
K. A. Hughes, S. P. Webster, B. R. Walker, Expert Opin. Invest. Drugs, 17(4), 481–496 (2008).
N. Takahashi, T. Kawada, T. Goto, et al., FEBS Lett., 550, 190–194 (2003).
Y. S. Lee, B. J. Lorenzo, T. Koufis, et al., Clin. Pharmacol. Ther., 59, 62–71 (1996).
Y. Feng, S. Huang, W. Dou, et al., Br. J. Pharmacol., 161, 113–126 (2010).
D. J. Hosfield, Y.Wu, R. J. Skene, et al., J. Biol. Chem., 280(6), 4639–4648 (2005).
J. Zhang, T. D. Osslund, M. H. Plant, et al., Biochemistry, 44, 6948–6957 (2005).
M. P. Thomas, B. V. L. Potter, Future Med. Chem., 3, 367–390 (2011).
S. P. Webster, T. D. Pallin, Expert Opin. Ther. Pat., 17(12), 1407–1422 (2007).
C. D. Boyle, T. J. Kowalski, Expert Opin. Ther. Pat., 19(6), 801–825 (2009).
C. Hale, M. Wang, Mini-Rev. Med. Chem., 8(7), 702–710 (2008).
M. M. Zhao, Pat. WO 2007038452; Chem. Abstr., 146, 401979 (2007).
S. T. Waddell, J. M. Balkovec, et al., Pat. WO 2007047625; Chem. Abstr., 146, 462263 (2007).
N. J. Kevin, G. Xin, et al., Pat. WO 2007087150; Chem. Abstr., 147, 235179 (2007).
K. Masuda, T. Ogawa, et al., Pat. WO 2008142986; Chem. Abstr., 150, 56140 (2009).
T. Ogawa, N. Chomei, et al., Pat. WO 2007114124; Chem. Abstr., 147, 553341 (2007).
K. W. Anderson, N. Fotouhi, et al., Pat. WO 2007107470; Chem. Abstr., 147, 406807 (2007).
R. Li, O. B. Wallace, et al., Pat. WO 2007127765; Chem. Abstr., 147, 522104 (2007).
J. S. York, O. B. Wallace, et al., Pat. WO 2007127901; Chem. Abstr., 147, 522101 (2007).
T. D. Aicher, P. B. Anzeveno, et al., Pat. WO 2007124254; Chem. Abstr., 147, 502351 (2007).
K. Harada, T. Ito, Pat. WO 2008069313; Chem. Abstr., 149, 53981 (2008).
H. Nakashima, T. Arako, et al., Pat. WO 2008142859; Chem. Abstr., 150, 5613 (2009).
D. Carniato, C. Leriche, et al., Pat. WO 2008052638; Chem. Abstr., 148, 538311 (2008).
A. Odermatt, Expert Opin. Ther. Pat., 19(10), 1477–1483 (2009).
Z.-K. Wan, E. Chenail, H.-Q. Li, J. Org. Chem., 76, 7048–7055 (2011).
B. Sorensen, M.Winn, J. Rohde, Bioorg. Med. Chem. Lett., 17, 527–532 (2007).
J. Rosenstock, S. Banarer, V. A. Fonseca, et al., Diabetes Care, 33, 1516–1522 (2010).
M. Ashiya, R. E. T. Smith, Nat. Rev. Drug Discovery, 6, 777–778 (2007).
H. Yki-Harvinen, N. Engl. J. Med., 351, 1106–1118 (2004).
E. G. Mohler, K. E. Browman, V. A. Roderwald, et al., J. Neurosci., 31, 5406–5413 (2011).
Author information
Authors and Affiliations
Additional information
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 47, No. 2, pp. 12 – 18, February, 2013.
Rights and permissions
About this article
Cite this article
Lipson, V.V., Shirobokova, M.G. & Petrova, O.N. 11β-Hydroxysteroid dehydrogenase type 1, a target for development of oral antidiabetic drugs (Review). Pharm Chem J 47, 80–86 (2013). https://doi.org/10.1007/s11094-013-0900-y
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11094-013-0900-y